在心房动中高风险的大动脉斑块:治疗困境
Shaniza Haniff1, Ashwin Shive Gowda2, Nawfal Al-Khafaji3
1Internal Medicine, University at Buffalo, New York, USA.
Cureus
|March 11, 2024
概括
由于中风风险,管理心房动 (AF) 和高风险的大动脉斑块是具有挑战性的. 这一案例证明了使用抗凝药,他类药物和监测的成功管理,避免了血栓栓塞并发症.
科学领域:
- 心脏病学 心脏病学
- 心血管外科心血管外科
- 神经学 神经学
背景情况:
- 心房动 (AF) 是一种与大动脉斑块相关的常见心律失常,增加了栓塞事件的风险,包括中风.
- 对于患有AF和高风险大动脉斑块的患者的治疗策略尚未成熟.
- 一名77岁的女性出现了新发的AF和高风险的上升性大动脉斑块.
研究的目的:
- 在患有高风险大动脉斑块的患者中管理新发性心房动的案例.
- 审查当前关于在存在高风险大动脉斑块的情况下管理AF的文献.
- 为这个复杂的患者群体提出一个管理方法.
主要方法:
- 采用了涉及心脏病学和心胸外科手术的多学科方法.
- 治疗包括抗凝药,他类药物治疗和定期成像监测.
- 由于血管栓塞风险高,心脏转移和心胸手术被推迟.
主要成果:
- 患者在没有任何血栓栓塞并发症的情况下成功管理.
- 选择的管理策略有效地解决了AF和高风险的大动脉斑块.
- 这种方法突出了类似复杂案件的潜在途径.
结论:
- 管理高风险大动脉斑块的AF需要仔细考虑栓塞风险.
- 抗凝药,他类药物和监测的组合可能是一个可行的策略.
- 需要进行进一步的研究和达成共识,以便为这一患者群建立最终的指导方针.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523
Anticoagulant Drugs: Low-Molecular-Weight Heparins
696
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
696


